Mutations targeting the coagulation pathway are enriched in brain metastases
نویسندگان
چکیده
منابع مشابه
Targeting Brain Metastases in Patients with Melanoma
Patients with brain metastases from malignant melanoma historically have a very poor outcome. Surgery and radiotherapy can be used, but for the majority of patients the disease will progress quickly. In the recent past, patients with brain metastases derived only minimal benefit from cytotoxic chemotherapy. Novel therapies that have been shown to be superior to chemotherapy in metastatic melano...
متن کاملTargeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases
Brain metastases are the most common cause of death in patients with metastatic melanoma, and the RAF-MEK-ERK and PI3K-AKT signaling pathways are key players in melanoma progression and drug resistance. The BRAF inhibitor vemurafenib significantly improved overall survival. However, brain metastases still limit the effectiveness of this therapy. In a series of patients, we observed that treatme...
متن کاملTargeting HER2 in brain metastases from breast cancer.
For many types of cancers, therapy aimed at a specific molecular target remains in the realm of clinical research. However, for breast cancer, rational therapeutics is routinely practiced in the clinic. For many years, oncologists have used tamoxifen to selectively treat women with estrogen receptorpositive breast cancer. Clinicians now screen breast cancer for HER2 overexpression, which occurs...
متن کاملRON tyrosine kinase mutations in brain metastases from lung cancer
RON mutations might identify actionable targets in highly aggressive lung tumours http://ow.ly/RTUp30hSBX6.
متن کاملBrain metastases in very young patients with lung cancer are still brain metastases.
Accessible online at: www.karger.com/onk Fax +49 761 4 52 07 14 E-mail [email protected] www.karger.com tases trials (61% of patients had lung cancer) identified three prognostic groups [9]. Favorable prognostic factors included KPS ≥ 70, age < 65 years, controlled primary tumor, and no extra-cranial metastases. Other studies have validated these results [10, 11]. RPA classification has als...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Scientific Reports
سال: 2017
ISSN: 2045-2322
DOI: 10.1038/s41598-017-06811-x